Head to Head Survey: CytRx (OTCMKTS:CYTR) vs. Adverum Biotechnologies (OTCMKTS:ADVM)

CytRx (OTCMKTS:CYTR) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Volatility and Risk

CytRx has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500.

Profitability

This table compares CytRx and Adverum Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CytRx N/A -31.45% -27.75%
Adverum Biotechnologies N/A -33.49% -28.81%

Earnings & Valuation

This table compares CytRx and Adverum Biotechnologies’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CytRx $250,000.00 33.64 -$12.71 million ($0.29) -0.86
Adverum Biotechnologies $1.61 million 458.53 -$72.63 million ($1.18) -9.69

CytRx has higher earnings, but lower revenue than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than CytRx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for CytRx and Adverum Biotechnologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytRx 0 0 1 0 3.00
Adverum Biotechnologies 0 4 2 0 2.33

CytRx currently has a consensus target price of $5.00, suggesting a potential upside of 1,900.00%. Adverum Biotechnologies has a consensus target price of $9.50, suggesting a potential downside of 16.89%. Given CytRx’s stronger consensus rating and higher probable upside, equities analysts plainly believe CytRx is more favorable than Adverum Biotechnologies.

Institutional and Insider Ownership

2.2% of CytRx shares are owned by institutional investors. Comparatively, 76.6% of Adverum Biotechnologies shares are owned by institutional investors. 6.9% of CytRx shares are owned by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

CytRx beats Adverum Biotechnologies on 8 of the 13 factors compared between the two stocks.

CytRx Company Profile

CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.